Category: Markets
Published: 2026-07-31T12:10:20.000Z
Moleculin Biotech, Inc. announced positive interim blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). The trial shows a 37% composite complete remission (CRc) rate, including in patients who previously failed venetoclax therapy, a significantly higher rate than published salvage remission rates. The company also highlighted the continued absence of cardiotoxicity, differentiating Annamycin from conventional anthracyclines.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.